A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl
A phase 2 trial of Epcoritamab, Lenalidomide, Ibrutinib in hodgkin lymphoma and non-hodgkin lymphoma, run by Genmab, active and no longer recruiting.
Overview
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT05283720 by Genmab, with 264 participants enrolled, started 2022-06-14 and due to reach its primary completion in 2032-11. Interventions recorded: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Prednisone, Lenalidomide.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Genmab, Prednisone, Lenalidomide, Rituximab.
- TrialSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.